血清OPG对PCI术后预后的预测价值被引量：1

The Predictive Value of Serum Osteoprotegerin for the Prognosis in Patients after PCI

下载PDF

导出

摘要探讨血清骨保护素(OPG)对冠脉介入术(PCI)患者预后的预测价值。选择2011年2月至2013年12月河北医科大学第三医院心内科行PCI的老年冠心病患者125例。检测不同时刻血清OPG水平(PCI术前、术后即刻、术后24小时、术后48小时、术后72小时,以及术后1个月、术后3个月、术后6个月,共8个时间点),记录术后6个月内心血管事件及支架内再狭窄情况。OPG水平和支架内再狭窄高度相关(OR=2.02,P<0.05)。OPG水平高者的心血管事件发生率大。血清OPG水平对PCI术后6个月的心血管事件和支架内再狭窄有较好的预测价值。 To explore the value of osteoprotegerin （OPG ） in prediction of cardiovascular events and restenosis of elderly coronary heart disease patients after percutaneous coronary intervention （PCI） from February 2011 to December 2013 in the Third Affiliated Hospital of Hebei Medical University .Serum OPG concentration of 125 individuals who underwent PCI was evaluated at different time ,including PCI preoperative ,postoperative immediately ,24h ,48h ,72h ,1 month ,3 months and 6 months after operation ,a total of 8 points .Cardiovascular events and ISR were recorded in 6 months after stenting by coronary angiograms .The results showed baseline OPG serum concentration ,measured before PCI ,was higher in ISR patients than those without ISR .The patients with higher OPG values were more susceptible to develop ISR （odd ratio ,2 .02;P〈0 .05） and at high risk for cardiovascular events .OPG serum level may be used as a clinically useful predictor for prognosis of elderly patients after PCI .

作者李海滨刘向东杨志慧姜志安张晓光王涛

机构地区河北医科大学第三医院心内科

出处《医学与哲学（B）》 2015年第6期32-34,共3页 Medicine & Philosophy(B)

基金河北省卫生厅科研基金项目项目编号:20120105

关键词骨保护素心血管事件支架内再狭窄经皮冠状动脉介入术 osteoprotegerin, cardiovascular events, in-stent restenosis, percutaneous coronary intervention

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献14

1童琳,余秀琼.骨保护素的临床研究进展[J].心血管病学进展,2013,34(1):150-153. 被引量：8
2冯模强,吕湛.骨保护素与心血管疾病研究进展[J].中华临床医师杂志（电子版）,2013,7(24):272-274. 被引量：3
3Malliga D E,Wagner D,Fahrleitner-Pammer A. The role of osteo- protegerin (OPG) receptor activator for nuclear factor kappaB lig- and (RANKL) in cardiovascular pathology-a review[J]. Wien Med Wochenschr, 2011,161 (23/24) : 565 -- 570.
4Simonet W S,Lacey D L,Dunstan C R,et al. Osteoprotegerin:a no- vel secreted protein involved in the regulation of bone density[J]. Cell, 1997,89(2):309--319.
5Kong Y Y,Yoshida H,Sarosi I,et al. OPGL is a key regulator of osteoclastogenesis,lymphocyte development and lymph-node orga- nogenesis[J]. Nature, 1999,397(6717) :315--323.
6Lacey D L,Timms E,Tan H L,et al. Osteoprotegerin ligand is a cy- tokine that regulates osteoclast differentiation and activation[J]. Cell, 1998,93(2): 165 -- 176.
7文娱,陈雪梅.骨保护素在临床中的应用进展[J].中国当代医药,2013,20(3):12-13. 被引量：6
8Fuernau G, Zaehringer S, Eitel I, et al. Osteoprotegerin in ST eleva tion myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging[J]. Int J Cardiol,2013,167(5):2134 2139.
9谢钦菁,罗助荣.骨保护素作为预测心血管疾病发病率和死亡率的新标志物的研究进展[J].中华临床医师杂志（电子版）,2011,5(10):2963-2966. 被引量：5
10Jono S, Otsuki S, Higashikuni Y, et al. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery dis ease[J].J Thromb Haemost,2010,8(6):1170 1175.

二级参考文献72

1罗助荣,张克己,郑磊磊,徐高阳,谢菁菁,林毅,盖晓波.血清骨保护素、可溶性核因子κB受体活化因子配体与急性冠状动脉综合征相关性研究[J].中华临床医师杂志（电子版）,2011,5(10):2886-2889. 被引量：8
2曾天舒,陈璐璐,潘世秀,夏文芳.补肾法对去卵巢大鼠骨髓细胞OPG、RANKL和TNF-α基因表达的影响[J].中国骨质疏松杂志,2006,12(4):323-326. 被引量：11
3向光大,孙慧伶,赵林双,侯洁,乐岭,徐琳.1型糖尿病患者胰岛素治疗前后血浆护骨素的变化[J].中华医学杂志,2007,87(18):1234-1237. 被引量：32
4王慎,田陈丽.骨保护素与糖尿病及其血管并发症[J].国际内分泌代谢杂志,2007,27(6):409-411. 被引量：1
5Simonet WS,Laeey DL,Dunstan CR. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J].{H}CELL,1997.309-319.
6Anderson DM,Maraskovasky E,BiHingsley WL. A homologue of the TNF receptor and its ligand enchance T-cell growth and dendritic cell function[J].{H}NATURE,1997.175-179.
7Kostenuik PJ,Nguyen HQ,McCabe J. Denosumab,a fully human monoclonal antibody to RANKL,inhibits bone resorption and increases BMD in knock-in mice that express chimeric(murine/human)RANKL[J].{H}Journal of Bone and Mineral Research,2009.182-195.
8Darnay BG,Haridas V. Characterization of the intra-cellular do-main of receptor activator of NF-κB(RANK)[J].{H}Journal of Biological Chemistry,1998.20551-20555.
9St?pień E,Wypasek E,Stopyra K. Increased levels of bone remodeling biomarkers(osteoprotegerin and osteopontin)in hypertensive individuals[J].{H}CLINICAL BIOCHEMISTRY,2011.826-831.
10Blazquez-Medela AM,Garcia-Ortiz L,Gomez-Marcos MA. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes[J].{H}European Journal of Clinical Investigation,2012.548-556.